BPC-157 is the most under-discussed thing on this board
Thinking out loud about this: BPC-157 is the most under-discussed thing on this board.
The three questions, kept separate, because this board runs them together constantly.
Identity: is this the sequence I ordered? Answered by mass spectrometry against a theoretical mass. Quantity: how much peptide is in the vial? Answered by net peptide content, not by area percent. Stability: what happens to it in solution over time? Answered by a stability statement with conditions attached, and almost never asked for.
A certificate that answers one of the three is common. One that answers all three is rare and worth choosing a supplier over. Nothing here is approved for human use in any case, so all three are questions about material rather than about anything else.
It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.
Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.
Sceptical readings welcome. The confident ones are the ones I distrust.
best — the order this archive was captured in
Left up. It distinguishes rodent work from human work, which is the standard on this board.
[deleted]
identity testing matters more here than purity does
Has anyone posted an independent result on that batch?
ask for the mass spectrum, not just the purity number
preclinical enthusiasm is not clinical evidence
the human evidence is thin and the rodent evidence is not
the human evidence is thin and the rodent evidence is not
Disagreeing with this line: that paper is in a rodent model and it is being quoted as a human result.
The evidence base, described honestly, which almost no summary of it does.
The published literature is overwhelmingly preclinical and largely in rodent models. The individual papers are generally more modest in their claims than the summaries that circulate. Human clinical trial evidence for the claims most often repeated in these threads is very limited.
That is not an argument that nothing is happening in the preclinical work — some of it is genuinely interesting. It is an argument that the distance between "this happened in a rodent model" and "this will happen in a person" is large, uncertain, and crossed silently in nearly every confident post on this board, including some of mine from two years ago.
Kept a reconstituted vial too long out of curiosity and learned something about solution stability I would rather have read.
Sent a vial to Janoshik: 99.4% against a claimed 98.5%, with the mass confirming the sequence. Both halves mattered to me.
What method produced that purity number?
Cosigning that the papers are more modest than the summaries of them. That is true across this whole site and especially here.
Disagree — that is a rodent study and you are stating it as a human effect. The distance between those is the entire argument.
Was there identity confirmation, or only a purity figure?
Paid for identity confirmation rather than just purity for the first time here. Worth it, and it is not the default on most certificates.
- 1Left up. It distinguishes rodent work from human work, which is the standard…8 comments in this branch · started by u/bpc_sceptic
- 2The evidence base, described honestly, which almost no summary of it does.…6 comments in this branch · started by u/source_or_silence